ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,262.08
1.38%
Dow Jones
44,296.51
0.97%
Gold vs US Dollar
2,715.28
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,561.63
-0.48%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) News

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACRV
DateTimeSourceHeadlineSymbolCompany
18/11/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202421:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202412:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202412:00GlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
21/10/202420:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
17/10/202412:00GlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
16/10/202420:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202412:00GlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
03/10/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/09/202410:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
14/09/202407:10GlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
10/09/202412:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
09/09/202411:00GlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
23/08/202420:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202420:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202412:00GlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202411:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Your Recent History

LSE
TPL
Tethys
LSE
OCDO
Ocado
LSE
VAST
Vast Resources
LSE
LLOY
Lloyds Banking
LSE
SYME
Supply@me Capital
NASDAQ
SMCI
Super Micro Computer
LSE
MIN
Minoan
LSE
POS
Plexus
LSE
NESF
Nextenergy Solar
LSE
ITV
Itv
LSE
GGP
Greatland Gold
LSE
CARD
Card Factory
LSE
CPI
Capita
LSE
JLP
Jubilee Metals
LSE
MARS
Marston's
LSE
SRSP
Sirius Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06